Charles Schwab Investment Management Inc. Purchases 41,250 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Charles Schwab Investment Management Inc. increased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 5.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 790,837 shares of the biopharmaceutical company’s stock after purchasing an additional 41,250 shares during the period. Charles Schwab Investment Management Inc. owned 0.75% of Revance Therapeutics worth $4,104,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Arizona State Retirement System raised its position in shares of Revance Therapeutics by 27.6% during the 2nd quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,996 shares during the period. Sei Investments Co. increased its holdings in Revance Therapeutics by 52.5% in the 2nd quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 7,628 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Revance Therapeutics by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,161 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 7,890 shares during the last quarter. California State Teachers Retirement System increased its holdings in Revance Therapeutics by 9.8% in the 1st quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 8,668 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Revance Therapeutics by 29.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 42,296 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 9,601 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Revance Therapeutics Trading Down 0.3 %

RVNC stock opened at $3.08 on Friday. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $9.74. The company has a 50-day moving average price of $4.60 and a 200 day moving average price of $4.46. The stock has a market cap of $323.09 million, a PE ratio of -1.60 and a beta of 0.81.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. Sell-side analysts forecast that Revance Therapeutics, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

RVNC has been the topic of a number of research reports. Barclays reiterated an “equal weight” rating and issued a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Mizuho reduced their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday. StockNews.com started coverage on shares of Revance Therapeutics in a report on Thursday. They issued a “hold” rating on the stock. HC Wainwright reissued a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.96.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.